{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T21:10:31Z","timestamp":1775077831046,"version":"3.50.1"},"reference-count":71,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2015,8,1]],"date-time":"2015-08-01T00:00:00Z","timestamp":1438387200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"PhD Scholarship from the Royal City of Dublin Hospital"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Experimental Cell Research"],"published-print":{"date-parts":[[2015,8]]},"DOI":"10.1016\/j.yexcr.2014.12.001","type":"journal-article","created":{"date-parts":[[2014,12,12]],"date-time":"2014-12-12T08:49:01Z","timestamp":1418374141000},"page":"1-14","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["Carboplatin and taxol resistance develops more rapidly in functional BRCA1 compared to dysfunctional BRCA1 ovarian cancer cells"],"prefix":"10.1016","volume":"336","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9687-1614","authenticated-orcid":false,"given":"Steven","family":"Busschots","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sharon","family":"O\u2019Toole","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John J.","family":"O\u2019Leary","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Britta","family":"Stordal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.yexcr.2014.12.001_bib1","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1056\/NEJMcp0901926","article-title":"Screening for ovarian cancer","volume":"361","author":"Clarke-Pearson","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.yexcr.2014.12.001_bib2","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1525-1438.2005.15351.x","article-title":"Treatment goals in ovarian cancer","volume":"15","author":"Ozols","year":"2005","journal-title":"Int. J. Gynecol. Cancer"},{"issue":"4-6","key":"10.1016\/j.yexcr.2014.12.001_bib3","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1159\/000086967","article-title":"Current concepts of treatment strategies in advanced or recurrent ovarian cancer","volume":"68","author":"Salzberg","year":"2005","journal-title":"Oncology"},{"issue":"12","key":"10.1016\/j.yexcr.2014.12.001_bib4","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.1002\/cncr.21536","article-title":"BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases","volume":"104","author":"Pal","year":"2005","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.yexcr.2014.12.001_bib5","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1086\/318787","article-title":"Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer","volume":"68","author":"Risch","year":"2001","journal-title":"Am. J. Hum. Genet."},{"issue":"4","key":"10.1016\/j.yexcr.2014.12.001_bib6","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1016\/S0002-9378(98)70476-4","article-title":"BRCA1, BRCA2, and hereditary nonpolyposis colorectal cancer gene mutations in an unselected ovarian cancer population: relationship to family history and implications for genetic testing","volume":"178","author":"Rubin","year":"1998","journal-title":"Am. J. Obstet. Gynecol."},{"issue":"22","key":"10.1016\/j.yexcr.2014.12.001_bib7","doi-asserted-by":"crossref","first-page":"3570","DOI":"10.1200\/JCO.2009.27.2997","article-title":"Somatic mutations in BRCA1 and BRCA2 could expand the number of patients that benefit from poly (ADP Ribose) polymerase inhibitors in ovarian cancer","volume":"28","author":"Hennessy","year":"2010","journal-title":"J. Clin. Oncol."},{"issue":"9698","key":"10.1016\/j.yexcr.2014.12.001_bib8","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1016\/S0140-6736(09)61338-6","article-title":"Ovarian cancer","volume":"374","author":"Hennessy","year":"2009","journal-title":"Lancet"},{"issue":"9338","key":"10.1016\/j.yexcr.2014.12.001_bib9","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1016\/S0140-6736(02)11087-7","article-title":"BRCA1: mechanisms of inactivation and implications for management of patients","volume":"360","author":"Kennedy","year":"2002","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.yexcr.2014.12.001_bib10","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1097\/PPO.0b013e3181cf0204","article-title":"BRCA gene structure and function in tumor suppression: a repair-centric perspective","volume":"16","author":"Murphy","year":"2010","journal-title":"Cancer J. (Sudbury, Mass.)"},{"issue":"8","key":"10.1016\/j.yexcr.2014.12.001_bib11","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1016\/j.ctrv.2007.07.013","article-title":"A systematic review of platinum and taxane resistance from bench to clinic: an inverse relationship","volume":"33","author":"Stordal","year":"2007","journal-title":"Cancer Treat. Rev."},{"issue":"3","key":"10.1016\/j.yexcr.2014.12.001_bib12","doi-asserted-by":"crossref","first-page":"354","DOI":"10.2174\/156800909788166592","article-title":"A systematic review of genes involved in the inverse resistance relationship between cisplatin and paclitaxel chemotherapy: role of BRCA1","volume":"9","author":"Stordal","year":"2009","journal-title":"Curr. Cancer Drug Targets"},{"issue":"2","key":"10.1016\/j.yexcr.2014.12.001_bib13","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s10689-005-2832-5","article-title":"BRCA1 and BRCA2: chemosensitivity, treatment outcomes and prognosis","volume":"5","author":"Foulkes","year":"2006","journal-title":"Fam. Cancer"},{"issue":"18","key":"10.1016\/j.yexcr.2014.12.001_bib14","doi-asserted-by":"crossref","first-page":"8949","DOI":"10.1158\/0008-5472.CAN-06-1495","article-title":"A mouse model for the molecular characterization of BRCA1-associated ovarian carcinoma","volume":"66","author":"Xing","year":"2006","journal-title":"Cancer Res."},{"issue":"45","key":"10.1016\/j.yexcr.2014.12.001_bib15","doi-asserted-by":"crossref","first-page":"6597","DOI":"10.1038\/sj.onc.1204812","article-title":"Inhibition of BRCA1 leads to increased chemoresistance to microtubule-interfering agents, an effect that involves the JNK pathway","volume":"20","author":"Lafarge","year":"2001","journal-title":"Oncogene"},{"issue":"19","key":"10.1016\/j.yexcr.2014.12.001_bib16","first-page":"6221","article-title":"BRCA1 functions as a differential modulator of chemotherapy-induced apoptosis","volume":"63","author":"Quinn","year":"2003","journal-title":"Cancer Res."},{"issue":"8","key":"10.1016\/j.yexcr.2014.12.001_bib17","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1038\/sj.bjc.6600859","article-title":"BRCA1 expression modulates chemosensitivity of BRCA1-defective HCC1937 human breast cancer cells","volume":"88","author":"Tassone","year":"2003","journal-title":"Br. J. Cancer"},{"issue":"3","key":"10.1016\/j.yexcr.2014.12.001_bib18","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/j.molonc.2012.12.007","article-title":"BRCA1\/2 mutation analysis in 41 ovarian cell lines reveals only one functionally deleterious BRCA1 mutation","volume":"7","author":"Stordal","year":"2013","journal-title":"Mol. Oncol."},{"issue":"3","key":"10.1016\/j.yexcr.2014.12.001_bib19","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1002\/ijc.2910450306","article-title":"Metallothionein gene expression and resistance to cisplatin in human ovarian cancer","volume":"45","author":"Schilder","year":"1990","journal-title":"Int. J. Cancer"},{"issue":"1","key":"10.1016\/j.yexcr.2014.12.001_bib20","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1006\/abio.1996.0383","article-title":"An acid phosphatase assay for quantifying the growth of adherent and nonadherent cells","volume":"241","author":"Yang","year":"1996","journal-title":"Anal. Biochem."},{"issue":"7","key":"10.1016\/j.yexcr.2014.12.001_bib21","doi-asserted-by":"crossref","first-page":"e40717","DOI":"10.1371\/journal.pone.0040717","article-title":"Resistance to paclitaxel in a cisplatin-resistant ovarian cancer cell line is mediated by P-Glycoprotein","volume":"7","author":"Stordal","year":"2012","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.yexcr.2014.12.001_bib22","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/0006-2952(82)90249-0","article-title":"Reduction in glutathione content of L-PAM resistant L1210 Cells confers drug sensitivity","volume":"31","author":"Suzukake","year":"1982","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.yexcr.2014.12.001_bib23","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.mex.2014.11.002","article-title":"Non-invasive and non-destructive measurements of confluence in cultured adherent cell lines","volume":"2","author":"Busschots","year":"2015","journal-title":"MethodsX"},{"issue":"3","key":"10.1016\/j.yexcr.2014.12.001_bib24","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/S0959-8049(97)89009-0","article-title":"Extended phase II study of paclitaxel as a 3-h infusion in patients with ovarian cancer previously treated with platinum","volume":"33","author":"du Bois","year":"1997","journal-title":"Eur. J. Cancer"},{"issue":"1","key":"10.1016\/j.yexcr.2014.12.001_bib25","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.1999.17.1.409","article-title":"Review of the comparative pharmacology and clinical activity of cisplatin and carboplatin","volume":"17","author":"Go","year":"1999","journal-title":"J. Clin. Oncol."},{"issue":"9332","key":"10.1016\/j.yexcr.2014.12.001_bib26","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/S0140-6736(02)09738-6","article-title":"Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial","volume":"360","author":"ICON3","year":"2002","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.yexcr.2014.12.001_bib27","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.1158\/1078-0432.CCR-05-2069","article-title":"Quantitative effect of gender, age, liver function, and body size on the population pharmacokinetics of paclitaxel in patients with solid tumors","volume":"12","author":"Joerger","year":"2006","journal-title":"Clin. Cancer Res."},{"issue":"3","key":"10.1016\/j.yexcr.2014.12.001_bib28","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.ygyno.2009.11.026","article-title":"Single agent carboplatin versus carboplatin plus pegylated liposomal doxorubicin in recurrent ovarian cancer: final survival results of a SWOG (S0200) phase 3 randomized trial","volume":"116","author":"Markman","year":"2010","journal-title":"Gynecol. Oncol."},{"issue":"6","key":"10.1016\/j.yexcr.2014.12.001_bib29","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1007\/s002800051020","article-title":"The pharmacokinetics of a 1-h paclitaxel infusion","volume":"45","author":"Mross","year":"2000","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"3","key":"10.1016\/j.yexcr.2014.12.001_bib30","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1002\/j.1552-4604.1988.tb03134.x","article-title":"Clinical pharmacokinetics of carboplatin","volume":"28","author":"Oguri","year":"1988","journal-title":"J. Clin. Pharmacol."},{"issue":"17","key":"10.1016\/j.yexcr.2014.12.001_bib31","doi-asserted-by":"crossref","first-page":"3194","DOI":"10.1200\/JCO.2003.02.153","article-title":"Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a gynecologic oncology group study","volume":"21","author":"Ozols","year":"2003","journal-title":"J. Clin. Oncol."},{"issue":"29","key":"10.1016\/j.yexcr.2014.12.001_bib32","doi-asserted-by":"crossref","first-page":"4699","DOI":"10.1200\/JCO.2006.06.0913","article-title":"Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG","volume":"24","author":"Pfisterer","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.yexcr.2014.12.001_bib33","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1146\/annurev.med.48.1.353","article-title":"The development and clinical utility of the taxane class of antimicrotubule chemotherapy agents","volume":"48","author":"Rowinsky","year":"1997","journal-title":"Annu. Rev. Med."},{"issue":"22","key":"10.1016\/j.yexcr.2014.12.001_bib34","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1093\/jnci\/djh323","article-title":"Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma","volume":"96","author":"Vasey","year":"2004","journal-title":"J. Natl. Cancer Inst."},{"issue":"19","key":"10.1016\/j.yexcr.2014.12.001_bib35","doi-asserted-by":"crossref","first-page":"2989","DOI":"10.1016\/0006-2952(84)90598-7","article-title":"The effects of buthionine sulphoximine (BSO) on glutathione depletion and xenobiotic biotransformation","volume":"33","author":"Drew","year":"1984","journal-title":"Biochem. Pharmacol."},{"issue":"19","key":"10.1016\/j.yexcr.2014.12.001_bib36","first-page":"4595","article-title":"In vitro and in vivo reversal of multidrug resistance by GF120918, an acridonecarboxamide derivative","volume":"53","author":"Hyafil","year":"1993","journal-title":"Cancer Res."},{"issue":"4","key":"10.1016\/j.yexcr.2014.12.001_bib37","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1080\/10915810600746023","article-title":"Structure, function, expression, genomic organization, and single nucleotide polymorphisms of human ABCB1 (MDR1), ABCC (MRP), and ABCG2 (BCRP) efflux transporters","volume":"25","author":"Choudhuri","year":"2006","journal-title":"Int. J. Toxicol."},{"issue":"6","key":"10.1016\/j.yexcr.2014.12.001_bib38","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1002\/jps.23952","article-title":"PARP inhibitors as P-glyoprotein substrates","volume":"103","author":"Lawlor","year":"2014","journal-title":"J. Pharm. Sci."},{"issue":"7","key":"10.1016\/j.yexcr.2014.12.001_bib39","doi-asserted-by":"crossref","first-page":"661","DOI":"10.5732\/cjc.009.10666","article-title":"Establishment and biological characteristics of oxaliplatin-resistant human colon cancer cell lines","volume":"29","author":"Liu","year":"2010","journal-title":"Chin. J. Cancer"},{"issue":"6","key":"10.1016\/j.yexcr.2014.12.001_bib40","first-page":"2002","article-title":"Establishment and characterization of acquired resistance to the farnesyl protein transferase inhibitor R115777 in a human colon cancer cell line","volume":"8","author":"Smith","year":"2002","journal-title":"Clin. Cancer Res."},{"issue":"8","key":"10.1016\/j.yexcr.2014.12.001_bib41","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1093\/jnci\/92.8.642","article-title":"Transactivation of the metallothionein promoter in cisplatin-resistant cancer cells: a specific gene therapy strategy","volume":"92","author":"Vandier","year":"2000","journal-title":"J. Natl. Cancer Inst."},{"issue":"7","key":"10.1016\/j.yexcr.2014.12.001_bib42","doi-asserted-by":"crossref","first-page":"3070","DOI":"10.1073\/pnas.89.7.3070","article-title":"High resistance to cisplatin in human ovarian cancer cell lines is associated with marked increase of glutathione synthesis","volume":"89","author":"Godwin","year":"1992","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"issue":"6B","key":"10.1016\/j.yexcr.2014.12.001_bib43","first-page":"4559","article-title":"Development of rational in vitro models for drug resistance in breast cancer and modulation of MDR by selected compounds","volume":"26","author":"Kars","year":"2006","journal-title":"Anticancer Res."},{"issue":"9","key":"10.1016\/j.yexcr.2014.12.001_bib44","first-page":"4379","article-title":"Alkylating agents: in vitro studies of cross-resistance patterns in human cell lines","volume":"46","author":"Teicher","year":"1986","journal-title":"Cancer Res."},{"issue":"10","key":"10.1016\/j.yexcr.2014.12.001_bib45","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1038\/sj.bjc.6602221","article-title":"A new superinvasive in vitro phenotype induced by selection of human breast carcinoma cells with the chemotherapeutic drugs paclitaxel and doxorubicin","volume":"91","author":"Glynn","year":"2004","journal-title":"Br. J. Cancer"},{"issue":"4","key":"10.1016\/j.yexcr.2014.12.001_bib46","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1002\/ijc.20230","article-title":"Enhanced in vitro invasiveness and drug resistance with altered gene expression patterns in a human lung carcinoma cell line after pulse selection with anticancer drugs","volume":"111","author":"Liang","year":"2004","journal-title":"Int. J. Cancer"},{"issue":"2","key":"10.1016\/j.yexcr.2014.12.001_bib47","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1007\/s12032-011-9889-9","article-title":"ER\u2212\/ER+ breast cancer cell lines exhibited different resistance to paclitaxel through pulse selection","volume":"29","author":"Ying","year":"2012","journal-title":"Med. Oncol."},{"issue":"5","key":"10.1016\/j.yexcr.2014.12.001_bib48","first-page":"1163","article-title":"Biological comparison of ovarian cancer resistant cell lines to cisplatin and taxol by two different administrations","volume":"17","author":"Yan","year":"2007","journal-title":"Oncol. Rep."},{"issue":"6","key":"10.1016\/j.yexcr.2014.12.001_bib49","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1007\/s002800050424","article-title":"In vitro schedule-dependent interaction between paclitaxel and cisplatin in human carcinoma cell lines","volume":"37","author":"Kano","year":"1996","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"10","key":"10.1016\/j.yexcr.2014.12.001_bib50","first-page":"2425","article-title":"Cisplatin inhibits paclitaxel-induced apoptosis in cisplatin-resistant ovarian cancer cell lines: possible explanation for failure ofcombination therapy","volume":"59","author":"Judson","year":"1999","journal-title":"Cancer Res."},{"issue":"5","key":"10.1016\/j.yexcr.2014.12.001_bib51","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1002\/ijc.2910620518","article-title":"Sequence-dependent antitumor activity of paclitaxel (taxol) and cisplatin in vivo","volume":"62","author":"Milross","year":"1995","journal-title":"Int. J. Cancer"},{"issue":"4 Suppl. 9","key":"10.1016\/j.yexcr.2014.12.001_bib52","first-page":"78","article-title":"Dose-finding and sequencing study of paclitaxel and carboplatin in non-small cell lung cancer","volume":"22","author":"Giaccone","year":"1995","journal-title":"Semin. Oncol."},{"issue":"1","key":"10.1016\/j.yexcr.2014.12.001_bib53","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1200\/JCO.1997.15.1.317","article-title":"Pharmacokinetics of paclitaxel and carboplatin in a dose-escalating and dose-sequencing study in patients with non-small-cell lung cancer. The European Cancer Centre","volume":"15","author":"Huizing","year":"1997","journal-title":"J. Clin. Oncol."},{"issue":"19","key":"10.1016\/j.yexcr.2014.12.001_bib54","doi-asserted-by":"crossref","first-page":"8961","DOI":"10.1158\/0008-5472.CAN-05-1187","article-title":"CpG island methylation of DNA damage response genes in advanced ovarian cancer","volume":"65","author":"Teodoridis","year":"2005","journal-title":"Cancer Res."},{"issue":"24","key":"10.1016\/j.yexcr.2014.12.001_bib55","doi-asserted-by":"crossref","first-page":"7413","DOI":"10.1158\/1078-0432.CCR-07-1083","article-title":"BRCA1 mRNA expression levels predict for overall survival in ovarian cancer after chemotherapy","volume":"13","author":"Quinn","year":"2007","journal-title":"Clin. Cancer Res."},{"issue":"16","key":"10.1016\/j.yexcr.2014.12.001_bib56","doi-asserted-by":"crossref","first-page":"2396","DOI":"10.1038\/sj.onc.1206319","article-title":"Role of BRCA1 in cellular resistance to paclitaxel and ionizing radiation in an ovarian cancer cell line carrying a defective BRCA1","volume":"22","author":"Zhou","year":"2003","journal-title":"Oncogene"},{"issue":"3","key":"10.1016\/j.yexcr.2014.12.001_bib57","doi-asserted-by":"crossref","first-page":"257","DOI":"10.2174\/0929867033368484","article-title":"Cisplatin biochemical mechanism of action: from cytotoxicity to induction of cell death through interconnections between apoptotic and necrotic pathways","volume":"10","author":"Fuertes","year":"2003","journal-title":"Curr. Med. Chem."},{"issue":"1","key":"10.1016\/j.yexcr.2014.12.001_bib58","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/0163-7258(84)90025-1","article-title":"Taxol: an antimitotic agent with a new mechanism of action","volume":"25","author":"Manfredi","year":"1984","journal-title":"Pharmacol. Ther."},{"issue":"35","key":"10.1016\/j.yexcr.2014.12.001_bib59","doi-asserted-by":"crossref","first-page":"20235","DOI":"10.1074\/jbc.270.35.20235","article-title":"Characterization of the taxol binding site on the microtubule","volume":"270","author":"Rao","year":"1995","journal-title":"J. Biol. Chem."},{"issue":"1","key":"10.1016\/j.yexcr.2014.12.001_bib60","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1158\/1541-7786.MCR-06-0234","article-title":"Functional characterization of a novel BRCA1-null ovarian cancer cell line in response to ionizing radiation","volume":"5","author":"DelloRusso","year":"2007","journal-title":"Mol. Cancer Res."},{"issue":"11","key":"10.1016\/j.yexcr.2014.12.001_bib61","first-page":"3445","article-title":"Discovery of differentially expressed genes associated with paclitaxel resistance using cDNA array technology: analysis of interleukin (IL) 6, IL-8, and monocyte chemotactic protein 1 in the paclitaxel-resistant phenotype","volume":"5","author":"Duan","year":"1999","journal-title":"Clin. Cancer Res."},{"issue":"1-2","key":"10.1016\/j.yexcr.2014.12.001_bib62","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S0378-1119(99)00042-6","article-title":"TRAG-3, a novel gene, isolated from a taxol-resistant ovarian carcinoma cell line","volume":"229","author":"Duan","year":"1999","journal-title":"Gene"},{"issue":"2","key":"10.1016\/j.yexcr.2014.12.001_bib63","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1158\/1535-7163.MCT-05-0190","article-title":"Paclitaxel-resistant cells have a mutation in the paclitaxel-binding region of Beta-tubulin (Asp26Glu) and less stable microtubules","volume":"5","author":"Hari","year":"2006","journal-title":"Mol. Cancer Ther."},{"issue":"4","key":"10.1016\/j.yexcr.2014.12.001_bib64","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/S0006-2952(97)83383-7","article-title":"Acquisition of taxol resistance via P-glycoprotein- and non-P-glycoprotein-mediated mechanisms in human ovarian carcinoma cells","volume":"53","author":"Parekh","year":"1997","journal-title":"Biochem. Pharmacol."},{"issue":"9","key":"10.1016\/j.yexcr.2014.12.001_bib65","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1097\/IGC.0b013e31826e2382","article-title":"Establishment of paclitaxel-resistant cell line and the underlying mechanism on drug resistance","volume":"22","author":"Zhang","year":"2012","journal-title":"Int. J. Gynecol. Cancer"},{"issue":"17","key":"10.1016\/j.yexcr.2014.12.001_bib66","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1093\/jnci\/djg036","article-title":"A randomized clinical trial of cisplatin\/paclitaxel versus carboplatin\/paclitaxel as first-line treatment of ovarian cancer","volume":"95","author":"du Bois","year":"2003","journal-title":"J. Natl. Cancer Inst."},{"issue":"3-4","key":"10.1016\/j.yexcr.2014.12.001_bib67","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/0165-7992(95)00033-X","article-title":"Characterization of carboplatin-resistant sublines derived from human larynx carcinoma cells","volume":"347","author":"Osmak","year":"1995","journal-title":"Mutat. Res. Lett."},{"issue":"2","key":"10.1016\/j.yexcr.2014.12.001_bib68","first-page":"257","article-title":"Development and characterization of five cell models for chemoresistance studies of human ovarian carcinoma","volume":"14","author":"Li","year":"2004","journal-title":"Int. J. Mol. Med."},{"issue":"1","key":"10.1016\/j.yexcr.2014.12.001_bib69","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.critrevonc.2004.09.007","article-title":"Copper transporters regulate the cellular pharmacology and sensitivity to Pt drugs","volume":"53","author":"Safaei","year":"2005","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"8","key":"10.1016\/j.yexcr.2014.12.001_bib70","article-title":"Abstract 821: developing a molecular understanding of non small cell lung cancer (NSCLC) resistance to platin-taxane chemotherapy","volume":"72","author":"Dalvi","year":"2012","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.yexcr.2014.12.001_bib71","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/1757-2215-5-40","article-title":"Distinct genetic alterations occur in ovarian tumor cells selected for combined resistance to carboplatin and docetaxel","volume":"5","author":"Armstrong","year":"2012","journal-title":"J. Ovarian Res."}],"container-title":["Experimental Cell Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014482714005278?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014482714005278?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T01:02:14Z","timestamp":1747184534000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014482714005278"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,8]]},"references-count":71,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,8]]}},"alternative-id":["S0014482714005278"],"URL":"https:\/\/doi.org\/10.1016\/j.yexcr.2014.12.001","relation":{},"ISSN":["0014-4827"],"issn-type":[{"value":"0014-4827","type":"print"}],"subject":[],"published":{"date-parts":[[2015,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Carboplatin and taxol resistance develops more rapidly in functional BRCA1 compared to dysfunctional BRCA1 ovarian cancer cells","name":"articletitle","label":"Article Title"},{"value":"Experimental Cell Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.yexcr.2014.12.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}